NASDAQ:MNOV MediciNova Q2 2026 Earnings Results & Report $1.28 -0.05 (-3.83%) As of 02:56 PM Eastern This is a fair market value price provided by Massive. Learn more. MediciNova beat analyst expectations on both earnings and revenue in its Q2 2026 results, released August 13, 2026. The company reported EPS of -$0.05 versus the -$0.0633 consensus estimate, while revenue of $458.44 thousand topped the $75 thousand estimate by $383.44 thousand. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 13, 2026TimeAfter Market ClosesConference Call7:00 AM ET MediciNova EPS ResultsActual EPS-$0.05Consensus EPS -$0.0633Beat/MissBeat by +$0.0133One Year Ago EPSN/AEPS Beat Rate6 of last 8 quartersMediciNova Revenue ResultsActual Revenue$458.44 thousandExpected Revenue$75 thousandBeat/MissBeat by +$383.44 thousandYoY Revenue GrowthN/AConference Call ResourcesQuarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) MediciNova Q2 2026 Earnings FAQ Did MediciNova beat earnings estimates for Q2 2026? MediciNova (NASDAQ:MNOV) reported earnings of -$0.05 per share for Q2 2026, beating the consensus estimate of -$0.0633. The report was announced on Thursday, August 13, 2026. What was MediciNova's revenue for Q2 2026? MediciNova reported revenue of $458.44 thousand for Q2 2026, against a consensus estimate of $75 thousand. MediciNova Earnings HeadlinesMedicinova IncNovember 14, 2026 | money.usnews.comMediciNova to Participate in the Maxim Growth SummitOctober 6, 2026 | globenewswire.comTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Trading's Thomas Wood calls it one of the firm's most powerful proprietary trading indicators, and says the company has never run a deal like this before. There are no strings attached, just a steep Black Friday discount on a tool built for traders.November 19 at 1:00 AM | Base Camp Trading (Ad)MediciNova stock tumbles on mixed Phase 2 NAFLD trial dataSeptember 28, 2026 | finance.yahoo.comMediciNova Shares Fall After Phase 2 Tipelukast Trial Misses Primary EndpointsSeptember 28, 2026 | finance.yahoo.comMediciNova Reports Phase 2 MN-001 Data In T2DM-Associated NAFLD; Stock Plunges In PremarketSeptember 28, 2026 | rttnews.comSee More MediciNova Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like MediciNova? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MediciNova and other key companies, straight to your email. Email Address About MediciNovaMediciNova (NASDAQ:MNOV) is a clinical-stage biopharmaceutical company that develops small-molecule drug candidates for neurological, pulmonary and other conditions. The company is based in La Jolla, California, and conducts research and clinical development through collaborations and studies in the United States and other countries. Its lead candidate, MN-166 (ibudilast), is being studied for several conditions, including amyotrophic lateral sclerosis, progressive multiple sclerosis and substance use disorders. MediciNova is also developing MN-001 (tipelukast) for potential uses in metabolic and fibrotic diseases. These candidates are investigational and have not been approved as medicines. MediciNova was founded in 2000. Yuichi Iwaki, M.D., Ph.D., is the company’s founder, president and chief executive officer.View MediciNova ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting GameWalmart Earnings Change the Narrative as Digital Growth Lifts OutlookWhatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play ItLowe's Earnings Beat Looked Strong Until a 34-Cent Tariff Refund Changed the MathApple's Next Margin Defense Could Be Hiding in Your WalletThe Uranium Price Paradox: 5 Investments Facing Very Different Tests in 2027Target Stock Is Up Over 70%—Has the Easy Money Already Been Made? Upcoming Earnings Hewlett Packard Enterprise (11/23/2026)Medtronic (11/24/2026)Analog Devices (11/24/2026)Autodesk (11/24/2026)Dell Technologies (11/24/2026)Deere & Company (11/25/2026)CrowdStrike (12/1/2026)Marvell Technology (12/1/2026)Bank Of Montreal (12/2/2026)Bank of Nova Scotia (12/2/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.